Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Grande Portage Resources (V.GPG) Initiates Sensor-Based Ore Sorting Testwork (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Tumbleweed67on Jul 16, 2010 4:24pm
489 Views
Post# 17275950

RE: The Site is Not Wrong ... It is just bad web d

RE: The Site is Not Wrong ... It is just bad web dHe's right, it is still there...just hidden. Though I didn't realize this was such an issue?

UPCOMING MILESTONES

Q1 10
Completed patient enrollment in modified REGENESIS Phase IIb acute ischemic stroke trial completed
Q2 10
Reported Top-line modified REGENESIS Phase IIb stroke trial data May 25, 2010 completed
H2 10
Initiate and enrol patients in a Phase IIa clinical study for traumatic brain injury
H2 10
Initiate clinical Proof-of-Concept study for multiple sclerosis
H2 10
Complete preclinical study for hemorrhagic stroke
H2 10
Complete 'end of Phase II' meeting with the FDA prior to initiating the Phase III stroke trial
©2004 - 2010 Stem Cell Therapeutics - All rights reserved
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities